Philippe Jamme

441 total citations
22 papers, 256 citations indexed

About

Philippe Jamme is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Philippe Jamme has authored 22 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Philippe Jamme's work include Lung Cancer Treatments and Mutations (10 papers), Liver physiology and pathology (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Philippe Jamme is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Liver physiology and pathology (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Philippe Jamme collaborates with scholars based in France, United States and Italy. Philippe Jamme's co-authors include Alexis B. Cortot, Zoulika Kherrouche, David Tulasne, Simon Baldacci, Marie‐Christine Copin, V. Grégoire, Marie Fernandes, Fabienne Escande, Matthieu Jamme and Laurent Mortier and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Annals of Oncology.

In The Last Decade

Philippe Jamme

21 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe Jamme France 9 149 110 106 84 45 22 256
Xuejing Aimee Wang United States 8 161 1.1× 126 1.1× 131 1.2× 116 1.4× 36 0.8× 15 294
Shiaowen David Hsu United States 10 122 0.8× 181 1.6× 102 1.0× 66 0.8× 46 1.0× 37 313
Simon Baldacci France 10 244 1.6× 145 1.3× 139 1.3× 107 1.3× 60 1.3× 24 364
Soheil Yala United States 4 103 0.7× 119 1.1× 171 1.6× 98 1.2× 41 0.9× 6 288
Karin Berghoff Germany 8 123 0.8× 134 1.2× 120 1.1× 69 0.8× 26 0.6× 28 277
Yau H. Yu Hong Kong 2 277 1.9× 164 1.5× 104 1.0× 83 1.0× 66 1.5× 2 331
Wen-Son Hsieh United States 6 138 0.9× 177 1.6× 135 1.3× 56 0.7× 62 1.4× 9 329
Meaghan Dendy United States 8 60 0.4× 105 1.0× 200 1.9× 89 1.1× 26 0.6× 11 345
Dafna Kaufman United States 8 59 0.4× 89 0.8× 130 1.2× 124 1.5× 39 0.9× 10 257
Tanguy Y. Seiwert United States 6 178 1.2× 82 0.7× 79 0.7× 51 0.6× 18 0.4× 7 271

Countries citing papers authored by Philippe Jamme

Since Specialization
Citations

This map shows the geographic impact of Philippe Jamme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Jamme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Jamme more than expected).

Fields of papers citing papers by Philippe Jamme

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Jamme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Jamme. The network helps show where Philippe Jamme may publish in the future.

Co-authorship network of co-authors of Philippe Jamme

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Jamme. A scholar is included among the top collaborators of Philippe Jamme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Jamme. Philippe Jamme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cescon, David W., Moira Rushton, Nathalie LeVasseur, et al.. (2025). IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast.. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations
2.
Jamme, Philippe, et al.. (2024). Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice. Melanoma Research. 34(2). 182–185. 2 indexed citations
3.
Bossi, Paolo, Irene Braña, Víctor Moreno, et al.. (2023). 362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC). Annals of Oncology. 34. S1610–S1611. 5 indexed citations
4.
Jamme, Philippe, Jean‐Baptiste Assié, Rémi Veillon, et al.. (2023). Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Targeted Oncology. 18(4). 585–591. 3 indexed citations
5.
Chevret, Sylvie, Maxime Battistella, Eve‐Marie Neidhardt, et al.. (2023). Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas. Cancer Immunology Immunotherapy. 72(8). 2649–2657. 3 indexed citations
6.
Jamme, Philippe, et al.. (2023). Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene. Melanoma Research. 33(3). 247–251. 3 indexed citations
7.
8.
Fernandes, Marie, Philippe Jamme, Alexis B. Cortot, Zoulika Kherrouche, & David Tulasne. (2021). When the MET receptor kicks in to resist targeted therapies. Oncogene. 40(24). 4061–4078. 22 indexed citations
9.
Jamme, Philippe, et al.. (2021). Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab. Therapeutic Advances in Medical Oncology. 13. 4277427525–4277427525. 3 indexed citations
10.
Baldacci, Simon, V. Grégoire, Enrico Patrucco, et al.. (2020). Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. Lung Cancer. 146. 366–369. 11 indexed citations
11.
Jamme, Philippe, Marie Fernandes, Marie‐Christine Copin, et al.. (2020). Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations. Journal of Thoracic Oncology. 15(5). 741–751. 60 indexed citations
12.
Baldacci, Simon, Martin Figeac, Martine Antoine, et al.. (2019). High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. Journal of Thoracic Oncology. 15(1). 120–124. 16 indexed citations
13.
Jamme, Philippe, Radj Gervais, Éric Dansin, et al.. (2019). Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. Clinical Lung Cancer. 20(4). 297–304.e1. 14 indexed citations
14.
Baldacci, Simon, Martin Figeac, Martine Antoine, et al.. (2019). P2.14-53 High MET Overexpression Does Not Predict the Presence of MET Exon 14 Splice Mutations in NSCLC: Results from the IFCT Predict.amm Study. Journal of Thoracic Oncology. 14(10). S851–S851. 2 indexed citations
15.
Mahjoubi, Linda, Franco Cecchi, Christophe Massard, et al.. (2018). Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori Journal. 104(6). NP38–NP41.
16.
Leprêtre, Frédéric, Fabienne Escande, Zoulika Kherrouche, et al.. (2018). Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients. Journal of Thoracic Oncology. 13(12). 1873–1883. 27 indexed citations
17.
Kherrouche, Zoulika, Simon Baldacci, Philippe Jamme, et al.. (2018). The multiple paths towards MET receptor addiction in cancer. Oncogene. 37(24). 3200–3215. 42 indexed citations
18.
Mortier, Laurent, Philippe Jamme, J.‐P. Lacour, et al.. (2018). Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.. Journal of Clinical Oncology. 36(15_suppl). 9520–9520. 4 indexed citations
19.
Bonneterre, Jacques, Jacques Bosq, Philippe Jamme, et al.. (2016). Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open. 1(4). e000072–e000072. 8 indexed citations
20.
Jamme, Philippe, et al.. (2015). Ipilimumab in anti-PD1 refractory metastatic melanoma. Melanoma Research. 26(2). 153–156. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xuejing Aimee Wang Breakdown of academic impact, for papers by Shiaowen David Hsu Breakdown of academic impact, for papers by Simon Baldacci Breakdown of academic impact, for papers by Soheil Yala Breakdown of academic impact, for papers by Karin Berghoff Breakdown of academic impact, for papers by Yau H. Yu Breakdown of academic impact, for papers by Wen-Son Hsieh Breakdown of academic impact, for papers by Meaghan Dendy Breakdown of academic impact, for papers by Dafna Kaufman Breakdown of academic impact, for papers by Tanguy Y. Seiwert
Rankless by CCL
2026